MicroRNA-365 regulates IL-1β-induced catabolic factor expression by targeting HIF-2α in primary chondrocytes

Hyun Sook Hwang1,2, Su Jin Park1,2, Mi Hyun Lee1,2 & Hyun Ah Kim1,2

Endothelial Per-Arnt-Sim domain protein-1/hypoxia-inducible factor-2α (EPAS-1/HIF-2α) is a catabolic transcription factor that regulates osteoarthritis (OA)-related cartilage destruction. Here, we examined whether microRNA-365 (miR-365) affects interleukin (IL)-1β-induced expression of catabolic factors in chondrocytes via regulation of HIF-2α. MiR-365 levels were significantly decreased in human OA cartilage relative to normal cartilage. Overexpression of miR-365 significantly suppressed IL-1β-induced expression of HIF-2α in human articular chondrocytes. Pharmacological inhibition of various IL-1β-associated signaling pathways revealed mitogen-activated protein kinase and nuclear factor-κB as the primary pathways driving IL-1β-mediated decreases in miR-365 and subsequent increase in HIF-2α expression. Using a luciferase reporter assay encoding the 3′ untranslated region (UTR) of human HIF-2α mRNA, we showed that overexpression of miR-365 significantly suppressed IL-1β-induced up-regulation of HIF-2α. AGO2 RNA-immunoprecipitation (IP) assay demonstrated that miR-365 and HIF-2α mRNA were enriched in the AGO2-IP fraction in miR-365-transfected primary chondrocytes compared to miR-con-transfected cells, indicating that HIF-2α is a target of miR-365. Furthermore, miR-365 overexpression significantly suppressed IL-1β-induced expression of catabolic factors, including cyclooxygenase-2 and matrix metalloproteinase-1, -3 and -13, in chondrocytes. In pellet culture of primary chondrocytes miR-365 prevented IL-1β-stimulated extracellular matrix loss and matrix metalloproteinase-13 expression. MiR-365 regulates IL-1β-stimulated catabolic effects in human chondrocytes by modulating HIF-2α expression.

Osteoarthritis (OA) is a degenerative joint disease resulting from a variety of biomechanical and biochemical factors, leading to destruction of articular cartilage, synovial inflammation, and joint pain. Although OA is generally regarded as a non-inflammatory disease, various pro-inflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α, derived from the synovium and chondrocytes, have been shown to affect both the synthesis and destruction of cartilage matrix.

IL-1β is synthesized as a precursor (pro-IL-1β) and activated through a proteolytic cleavage by caspase-1. Activated IL-1β binds to type 1 receptor (IL-1R1) and activates several signal transduction pathways, including protein kinase C, mitogen activated protein kinase (MAPK), NF-kB and activator protein 1 (AP-1). In addition, IL-1β induces matrix metalloproteinase (MMP) expression via inducible nitric oxide synthase (iNOS) induction and NO production in rabbit articular chondrocytes. IL-1α was also detected in the cartilage and synovial fluids of patients with rheumatoid arthritis (RA) and OA, suggesting that IL-1α is an important mediator in the process of cartilage damage. Under the condition of hypoxic culture, IL-1β-stimulated activation of MAPK, NF-kB, and AP-1 was significantly enhanced in articular chondrocytes compared with normoxia. Recent studies have showed that IL-1β modulated two α subunits of hypoxia-inducible factor (HIF), HIF-1α and HIF-2α, in chondrocytes, suggesting a significance of HIF as a transcription regulator in chondrocytes during OA.

HIF, a transcription factor composed of an α and β subunit, modulates oxygen-regulated gene expression by binding to hypoxia response elements at target gene loci. Activity is mediated through the dimerization of either HIF-1α or HIF-2α with the HIF-1α subunit, resulting in distinct transcriptional responses. In particular,
miR-365 plays a crucial role in maintaining cartilage homeostasis. Prior to stimulation with IL-1β (1 ng/mL) for 6 h.

OA samples were obtained from the femoral head of patients \( n = 10, 70.1 \pm 12.5 \) years at the time of total knee replacement surgery. Patient diagnoses were determined using the criteria set forth by the American College of Rheumatology. Normal cartilage samples were obtained from the femoral head of patients \( n = 10, 70.1 \pm 12.5 \) years with femoral neck fractures and no known history of OA or RA. Sample was obtained only from grossly normal-looking cartilage. The collection and use of human tissue samples was reviewed and approved by the Institutional Review Board of Hallym University Sacred Heart Hospital, Anyang, Korea (approval number 2013-I022). All patients provided written informed consent. All methods were performed in accordance with the relevant guidelines and regulations of Hallym University and were approved by its ethical committee.

Chondrocytes were isolated by carefully dissecting articular cartilage from a relatively lesion-free area, followed by sequential digestion with a protease (8 \( \mu \)g/mL) from Streptomyces griseus for 1 h and with collagenase (4 \( \mu \)g/mL) from Clostridium histolyticum and hyaluronidase (0.2 \( \mu \)g/mL) from bovine testes (Sigma-Aldrich) for 2 h. Chondrocytes were maintained in monolayer culture in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 °C in a humidified atmosphere of 5% CO\(_2\) and 95% air. First-passage cultured chondrocytes were used within 7–10 days after seeding.

Materials and Methods

Collection of OA cartilage and chondrocytes. OA cartilage samples were obtained from the knee joints of OA patients \( n = 10, 71.9 \pm 7.1 \) years at the time of total knee replacement surgery. Patient diagnoses were determined using the criteria set forth by the American College of Rheumatology. Normal cartilage samples were obtained from the femoral head of patients \( n = 10, 70.1 \pm 12.5 \) years with femoral neck fractures and no known history of OA or RA. Sample was obtained only from grossly normal-looking cartilage. The collection and use of human tissue samples was reviewed and approved by the Institutional Review Board of Hallym University Sacred Heart Hospital, Anyang, Korea (approval number 2013-I022). All patients provided written informed consent. All methods were performed in accordance with the relevant guidelines and regulations of Hallym University and were approved by its ethical committee.

Chondrocytes were isolated by carefully dissecting articular cartilage from a relatively lesion-free area, followed by sequential digestion with a protease (8 \( \mu \)g/mL) from Streptomyces griseus for 1 h and with collagenase (4 \( \mu \)g/mL) from Clostridium histolyticum and hyaluronidase (0.2 \( \mu \)g/mL) from bovine testes (Sigma-Aldrich) for 2 h. Chondrocytes were maintained in monolayer culture in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 °C in a humidified atmosphere of 5% CO\(_2\) and 95% air. First-passage cultured chondrocytes were used within 7–10 days after seeding.

\( \text{SV}1353 \) cells, human chondrogenic cell line, were cultured in DMEM containing 10% FBS and 1% penicillin/streptomycin at 37 °C in a humidified atmosphere of 5% CO\(_2\) and 95% air for pellet culture.

To examine the effect of MAPK and NF-κB signaling pathway on miR-365 and HIF-2α expression, chondrocytes were pretreated with SF600125 (10 \( \mu \)M), SD98059 (10 \( \mu \)M), SB203580 (1 \( \mu \)M), and Bay 11-7082 (5 \( \mu \)M) 2 h prior to stimulation with IL-1β (1 ng/mL) for 6 h.

Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) to detect the expression of HIF-2α and miR-365. For isolation of total RNA from cartilage tissues, minced cartilage samples were ground to a fine powder in liquid nitrogen, and total RNA was isolated from chondrocytes using TRIzol reagent. For quantification of HIF-2α gene expression, cDNA was synthesized from 2 \( \mu \)g of RNA using Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI, USA). The qRT-PCR reactions contained SYBR Green PCR master mix, forward and reverse primer for HIF-2α, and an equal amount of cDNA from each sample. PCR amplification was performed under the condition of denaturation (95 °C for 15 sec) and anneal/extension (60 °C for 1 min) step for 40 cycles using a StepOnePlus real-time PCR system (Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control.
Primer sequences were as follows: HIF-2α forward 5′-GAG-GGT-TTC-ATT-GGT-GT-3′, HIF-2α reverse 5′-GCT-AGT-CTC-ATG-GT-3′; GAPDH forward 5′-TGA-CAT-CAA-GAA-GGT-GGT-GAA-G-3′; reverse 5′-TCC-CTG-GGG-ATG-GGC-AT-3′. Expression of mature miR-365 was quantitated using a Taqman miRNA reverse transcription kit and miRNA-specific primers obtained from Applied Biosystems (Foster, CA, USA) according to the manufacturer’s instructions. Purified RNA was reverse transcribed using the Taqman miRNA reverse transcription kit (Applied Biosystems) and miRNA-specific stem-loop RT primers (Applied Biosystems). PCR mixtures for miRNA detection contained 2 µL RT products, 5 µL TaqMan Universal PCR master mix, 0.2 µM Taqman probe, and 10 µM primers. qRT-PCR was performed using a StepOnePlus real-time PCR system (Applied Biosystems). RNU6B was used as an internal control for miRNA detection.

Transfection of miRNAs and small interfering RNAs (siRNA). HIF-2α siRNA (si-HIF-2α; sense 5′-CGU-GAG-AAC-CUG-AGU-CUC-A-3′; antisense 5′-UGC-GAG-UCA-GGU-UCU-CAC-G-3′), control siRNA (si-con; sense 5′-CCU-ACG-CCA-AUU-UCG-U-3′; antisense 5′-AGC-AAU-UUG -GUG-GCC-UAG-G-3′) as a negative control, the mature form of has-miR-365 (miR-365; 5′-UAA-UGC-CCC -UAA-AUA-UGC-UUA-U-3′), and nonspecific microRNA (miR-con; 5′-CCU-ACG-CCA-AAU-UCC-U-3′) as an off-target control were purchased from Bioneer (Daejeon, Korea). The antisense inhibitor of miR-365 (anti-miR-365) was obtained from Applied Biosystems. Human chondrocytes were transfected with miR-con, miR-365, or anti-miR-365 at a concentration of 50 nM using Lipofectamine according to the manufacturer’s instructions. In brief, miRNA or siRNA were gently mixed with plus reagent diluted with Opti-MEM media. After the diluted miRNA or siRNA was added to Lipofectamine reagent diluted with Opti-MEM, the solution containing miRNA or siRNA was gently mixed and incubated for 15 min at room temperature to allow miRNA- or siRNA-liposome complexes to form. The medium containing miRNA- or siRNA-liposome complexes was drop-wise added onto the chondrocytes and the cells were incubated for 3 h at 37 °C. The cells were maintained with fresh medium for 48 h. The cells were then stimulated with IL-1β (1 ng/mL) for 6 or 24 h and used for qRT-PCR and Western blot assays, respectively. In addition, to examine the effect of HIF-2α knockdown on IL-1β-stimulated catabolic factor expression in miR-365-stimulated chondrocytes, si-HIF-2α and miR-365 were co-transfected into the chondrocytes. Briefly, si-HIF-2α and/or miR-365 were prepared by gently pipetting in Opti-MEM media. Co-transfection complexes were drop-wise added to the chondrocytes with gently rocking the culture plate. After 3 h incubation the culture medium was replaced by fresh medium. Co-transfected chondrocytes were stimulated with IL-1β (1 ng/mL) for 6 or 24 h as described above.

Immunohistochemical analysis. Cartilage tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned using a microtome. Sections were blocked with 3% bovine serum albumin at room temperature for 1 h and incubated with anti-HIF-2α antibody (1: 100 dilution) for 16 h at 4 °C. Sections were then rinsed, incubated with biotinylated secondary antibody (1:200 dilution) for 30 min, and treated with Vectastatin ABC reagent (Vector Laboratories, Burlingame, CA, USA) for 30 min, and visualized with 3,3′-diaminobenzidine for 8 min. To quantify the protein level of HIF-2α in normal and OA cartilages, total number of chondrocytes and the number of chondrocytes staining positive for HIF-2α were evaluated and results were expressed as the percentage of chondrocytes staining positive in 2 different fields per section.

Enzyme-linked immunosorbent assay (ELISA). Cell culture medium was collected to measure the level of secreted MMP-13. MMP-13 protein levels were quantified using a pro-MMP-13 immunosorbent assay according to the manufacturer’s instructions (R&D Systems). Briefly, 100 µL of standard solution and sample was added to each well of 96-well plate, which was coated with MMP-13 antibody. Biotin-labeled detection antibody (100 µL) was added to the wells for 1 h at 37 °C. After washing with wash buffer, avidin-horse radish peroxidase (HRP) conjugate was added to each well at room temperature for 30 min and substrate reagent was added to each well for 15 min. The reactions were finished by adding stop solution to each well. Optical density was measured at 450 nm using a Thermo Scientific Multiskan GO Microplate Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). The concentrations (pg/mL) of MMP-13 of the samples were calculated from the standard curve.

Western blot analysis. Cell lysates were prepared with radioimmunoprecipitation assay (RIPA) lysis buffer (Biosesang, Kyunggi, Korea) and protein concentrations were quantified using bicinchoninic acid protein assay (Thermo Scientific, Rockford, IL, USA). Equal amount of proteins were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred to a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Hercules, CA, USA). The membrane was blocked with 5% (w/v) nonfat milk in TBST (Tris buffered saline and 0.1% Tween 20) and incubated with primary (1: 1,000 dilution) and secondary antibodies (1: 5,000 dilution). The membrane was developed using an enhanced chemiluminescence kit (Santa Cruz Biotechnology).

 Luciferase construct and reporter assay. The 3′UTR sequence (5′-UUUACCUCCUGCGUUAAAGGGC AUUUUACCCUUUGCAUUU-3′) of HIF-2α containing the putative miR-365 binding site were obtained from gene sequence databases, and used to design the wild-type HIF-2α 3′UTR-Luc plasmid (HIF-2α 3′UTR). Briefly, HIF-2α 3′UTR was amplified by PCR using forward primer 5′-CTC-GAG-AAA-GCA-CAT-TGG-GCC-ACC-TAT-TTA-GTA-AGG-CC-3′ and reverse primer 5′-GGC-GGC-GCT-GAA-GGT-GGT-GAA-GGA-3′, and cloned into a multiple cloning region in a psi-CHECK-2 vector (Promega). For construction of the mutant HIF-2α 3′UTR-Luc plasmid (mut HIF-2α 3′UTR), a mutant HIF-2α 3′UTR sequence was generated by site-directed mutagenesis. DNA substitution was introduced into HIF-2α 3′UTR plasmid by PCR using the following primer set: forward 5′-GGT-GCC-CTG-GCA-TTA-AGG-3′; reverse 5′-TGC-CTT-GTA-AGG-3′; and cloned into a multiple cloning region in a psi-CHECK-2 vector (Promega).
and reverse 5′-CTG-CAA-GGG-TAA-ACC-CAA-CTT-AAT-GAT-CAG-GAA-AC-3′ (the underlined nucleotide sequence indicates the substituted position). PCR reactions were conducted using a mixture of 0.7 μl Expand Long-range Enzyme Mix (Roche Diagnostics, Mannheim, Germany), 10 μl 5 × Expand Long-range Buffer, 100 ng template plasmid, 100 mM primers, 3 μl DMSO, and 2.5 μl dNTPs (10 mM). PCR cycling conditions were as follows: 92 °C for 30 s, 55 °C for 1 min, 68 °C for 10 min, and a final extension at 68 °C for 10 min. PCR products were incubated with DpnI at 37 °C for 1 h to digest methylated template DNA, and then transformed into DH5α Escherichia coli.

For reporter assays, cells were transfected with wild-type or mutant HIF-2α 3′UTR-Luc plasmid (50 nM) and miR-con, miR-365 or anti-miR-365 (50 nM) using Lipofectamine as described in section of transfection of miRNA and siRNA. Luciferase activity was measured with a Dual-Glo Luciferase Assay system (Promega) according to the manufacturer’s instructions.

Ribonucleoprotein immunoprecipitation assay (RNP IP assay). RNP IP assay was performed using RIP-Assay kit for microRNA (MBL, Nagoya, Japan) according to the manufacturer’s instructions. Briefly, harvested cells were lysed by incubation with lysis buffer on ice for 10 min, followed by centrifugation at 12,000 g for 5 min at 4 °C. The supernatant was precleared by incubation with 50% protein A agarose beads slurry in lysis buffer with rotating for 1 h at 4 °C and then incubated with IgG- or Argonaute 2 (AGO2)-immobilized beads for 3 h at 4 °C. IP with IgG was used as a negative control. After centrifugation, the antibody-immobilized beads-RNP complex was washed three times with wash buffer. For isolation of miRNA and target mRNA, the Ab-RNP complex was dissolved in protein digesting solution and RNA was precipitated by adding ice-cold 100% ethanol and incubation for 20 min at −20 °C. RNA precipitates were washed twice with ice cold 70% ethanol, dried up, and dissolved in nuclease-free water. RNA and protein from total (T; input sample taken before IP start), flow through (FT; sample from the supernatant of IP fraction), and IP fractions were prepared for qRT-PCR and western blot analysis. The levels of miR-365 and HIF-2α in RNA samples were measured as described in the section of qRT-PCR.

Pellet culture. Primary chondrocytes and SW1353 cells were incubated with miR-365 or miR-con (50 nM) diluted in Lipofectamine for 2 h. The pellets of miR-365- or miR-con-transfected cells were formed by centrifugation 4 × 10^5 cells at 300 g for 10 min and transferred into bottom round 96-well plate. The pellets were exposed to IL-1β (1 ng/mL) for 7 days. The medium was changed every second day for culture period and collected for measurement of MMP-13 level. For alcian blue staining, the pellets were fixed with 4% formaldehyde in PBS for 20 min at room temperature, washed three times with PBS, and stained with alcian blue solution for 2 h. Then, the pellets were rinsed with 0.1 M hydrochloric acid and washed twice with PBS.

Statistical analysis. Data are expressed as mean ± standard deviation (SD). Statistical analysis was performed using a Mann-Whitney U test (GraphPad Prism 6). A value of P < 0.05 was considered statistically significant.

Results

Altered expression of miR-365 and HIF-2α in OA compared to normal cartilage. Bioinformatics analysis of IL-1β-regulated miRNAs using miRanda, TargetScan, and PicTar revealed a putative binding site for miR-365 in the 3′UTR of the catabolic transcription factor HIF-2α. To examine the relationship between miR-365 and HIF-2α expression in OA progression, we compared the expression of miR-365 and HIF-2α in normal and OA cartilages. MiR-365 expression was significantly reduced in OA compared to normal cartilages (Fig. 1A), while HIF-2α mRNA level was increased in OA cartilage relative to controls (Fig. 1B). OA cartilages showed the loss of praxin-O staining, fibration of the cartilage with fissures, and the decreased number of chondrocytes compared to normal cartilage (Fig. 1C). In addition, the level of Hif-2α-positive cells was significantly higher in OA cartilage than normal cartilage (Fig. 1C and D).

MiR-365 and HIF-2α expression were related with IL-1β signaling pathways. To confirm that miR-365 is regulated by IL-1β, we investigated miR-365 expression in IL-1β-treated primary chondrocytes using qRT-PCR. IL-1β treatment (1 and 10 ng/mL) significantly inhibited miR365 expression for 6, 16, 24, and 48 h compared to IL-1β-un-treated cells (Fig. 2A). The suppression of miR-365 expression was not significantly different between 1 and 10 ng/mL of IL-1β except for at 16 h, when the decrease was only significant at 1 ng/mL concentration (Fig. 2A). In light of pathophysiological concentrations of IL-1 β in synovial fluids from patients with OA, we employed 1 ng/mL of IL-1β for our experiments. Having confirmed the role of IL-1β in miR-365 expression, we next examined the role of miR-365 expression on HIF-2α expression. Human primary chondrocytes were transfected with miR-365 and miR-con 48 h prior to IL-1β stimulation for 6 h. IL-1β was observed to significantly reduce miR-365 expression and increase HIF-2α expression compared to IL-1β-un-treated control (Fig. 2B). However, miR-365 transfection significantly inhibited the basal expression of HIF-2α in IL-1β-un-treated cells as well as IL-1β-induced HIF-2α expression (Fig. 2B). Taken together, these results demonstrate that miR-365 regulates IL-1β-induced HIF-2α expression.

Next, we sought to identify the IL-1β-activated signaling pathways that contribute to miR-365 and HIF-2α expression. Human chondrocytes were pretreated with SP600125 (JNK inhibitor), PD98059 (MEK-1/2 inhibitor), SB203580 (p38 MAPK inhibitor), and Bay 11-7082 (NF-κB inhibitor) for 2 h and then exposed to IL-1β for 6 h. These inhibitors at the concentrations employed in these experiments significantly inhibited the activation of MAPK and NF-κB pathways (Fig. 3A). MAPK and NF-κB inhibitors had no significant influence on the basal expression of miR-365 and HIF-2α (Fig. 3B and C). Pre-treatment with these inhibitors significantly attenuated the effects of IL-1β on miR-365 down-regulation, restoring its expression to levels at those of untreated control (Fig. 3B). At the same time, MAPK and NF-κB inhibitors significantly reduced HIF-2α expression in
IL-1β-treated primary chondrocytes (Fig. 3C). Therefore, these results demonstrate that both miR-365 and HIF-2α expression are regulated by IL-1β via MAPK and NF-κB.

HIF-2α expression was attenuated by the direct binding of miR-365 to the 3′UTR of HIF-2α mRNA. To investigate whether miR-365 directly interacts with the 3′UTR of HIF-2α mRNA, a luciferase reporter assay was performed using a DNA construct containing the 3′UTR of HIF-2α mRNA, which harbors a putative binding site of miR-365, and is highly conserved across diverse species (Fig. 4A). miR-365 was shown to significantly inhibit HIF-2α reporter activity relative to miR-con-treated cells, whereas transfection with anti-miR-365, the antisense inhibitor of miR-365, enhanced the reporter activity of HIF-2α (Fig. 4B, left).

Next, to confirm the association of miR-365 with HIF-2α, we examined the interaction of miR-365 or anti-miR-365 and a mutant reporter plasmid containing mutations in the miR-365 binding site of HIF-2α. The reporter activity data showed that a mutation in the miR-365 binding sequence removed miR-365-mediated inhibition or anti-miR-365-mediated enhancement of HIF-2α reporter activity (Fig. 4B, right).

To ensure that HIF-2α is the target of miR-365, we performed AGO2-RNP IP assay on miR-con- and miR-365-transfected chondrocytes. Western blot assay for checking the efficiency of RNP IP assay demonstrated that the efficiency of AGO2 immunoprecipitation (AGO2-IP) complex was comparable in miR-con- and miR-365-transfected cells (Fig. 4C). Both miR-365 and HIF-2α were abundantly presented in AGO2-IP fraction.
containing miR-365-RNA inducing silencing complex (RISC) complexes that were obtained using AGO2 antibody in miR-365-transfected cells compared to that of miR-con-transfected cells (Fig. 4D). Together, these data show that miR-365 suppresses HIF-2α expression by binding to the 3′UTR of HIF-2α mRNA.

**IL-1β-stimulated catabolic factors were reduced by miR-365 in chondrocytes.** HIF-2α is a crucial catabolic transcription factor in pro-inflammatory and OA processes. Given the effects of IL-1β on miR-365 and HIF-2α expression, we examined the potential regulatory effects of miR-365 on IL-1β-activated signaling pathways. To address this question, primary chondrocytes were transfected with miR-365 or a nonspecific miRNA control (miR-con) for 48 h and stimulated with IL-1β for 6 h. Expression of miR-365 and HIF-2α was measured using TaqMan miRNA and SYBR Green-based real-time PCR assays, respectively. RNU6B and GAPDH were used as endogenous controls. Data are expressed as the mean ± SD of duplicate data from more than three independent experiments. ns, not significant; *P < 0.05, **P < 0.01, and ****P < 0.001 vs. IL-1β-untreated cells. (B) Inhibitory effect of miR-365 on IL-1β-induced HIF-2α expression. Human chondrocytes were transfected with miR-365 or a nonspecific miRNA control (miR-con) for 48 h and stimulated with IL-1β for 6 h. Expression of miR-365 and HIF-2α was measured using TaqMan miRNA and SYBR Green-based real-time PCR assays, respectively. RNU6B and GAPDH were used as endogenous controls. Data are expressed as the mean ± SD of duplicate data from more than three independent experiments. ns, not significant; *P < 0.05, **P < 0.01, and ****P < 0.001 vs. IL-1β-untreated control; #P < 0.05, ##P < 0.005, and ####P < 0.001 vs. IL-1β + miR-365-transfected cells.

Figure 2. miR-365 significantly inhibits interleukin (IL)-1β-induced HIF-2α expression. (A) The effect of IL-1β on miR-365 expression in human OA chondrocytes. Human chondrocytes were exposed to IL-1β (1 or 10 ng/mL) for 6, 16, 24, and 48 h. Expression of miR-365 was measured using TaqMan miRNA real-time PCR assays. RNU6B was used as an endogenous control. Data are expressed as the mean ± SD of duplicate data from six independent experiments. ns, not significant, *P < 0.05, **P < 0.01 and ****P < 0.001 vs. IL-1β-untreated cells. (B) Inhibitory effect of miR-365 on IL-1β-induced HIF-2α expression. Human chondrocytes were transfected with miR-365 or a nonspecific miRNA control (miR-con) for 48 h and stimulated with IL-1β for 6 h. Expression of miR-365 and HIF-2α was measured using TaqMan miRNA and SYBR Green-based real-time PCR assays, respectively. RNU6B and GAPDH were used as endogenous controls. Data are expressed as the mean ± SD of duplicate data from more than three independent experiments. ns, not significant; *P < 0.05, **P < 0.01, and ****P < 0.001 vs. IL-1β-untreated control; #P < 0.05, ##P < 0.005, and ####P < 0.001 vs. IL-1β + miR-365-transfected cells.
MMP-1, in HIF-2α-knocked down chondrocytes compared to si-con-transfected cells (Fig. 6A–E). Furthermore, miR-365 transfection had no significant effect on COX-2 and iNOS as well as MMP-1, -3, and -13 expressions in the HIF-2α-knocked down chondrocytes (Fig. 6A–C). These results demonstrate that miR-365 functions as a regulator of IL-1β-induced pro-inflammatory and catabolic factors via modulation of HIF-2α. miR-365 prevented IL-1β-induced MMP-13 and loss of extracellular matrix (ECM) in pellet culture of chondrocytes. To investigate whether miR-365 suppresses loss of ECM induced by IL-1β, the pellet culture of miR-365-transfected chondrocytes was performed in DMEM containing IL-1β for 7 days. The pellet morphology data demonstrated that no significant changes were observed in the size of miR-con- and miR-365-transfected primary chondrocyte and SW1353 cell pellets in the absence of IL-1β (Fig. 7A). However, miR-365 suppressed the reduction of pellet size induced by IL-1β, which significantly reduced the size of miR-con-transfected pellet (Fig. 7A). In addition, alcian blue staining for ECM showed that IL-1β caused fragile cell masses and weak staining in miR-con-transfected group, whereas miR-365 significantly prevented IL-1β-induced changes in cell mass and ECM matrix (Fig. 7A). In addition, the concentrations of MMP-13 protein released from pellet culture of primary chondrocytes and SW1353 cells were measured by ELISA. As expected, the secreted MMP-13 levels in both IL-1β-untreated and IL-1β-stimulated pellet culture of primary chondrocytes and SW1353 cells were significantly suppressed by miR-365 transfection compared to the miR-con transfected groups (Fig. 7B). Taken together, these data demonstrated that miR-365 significantly suppressed IL-1β-induced catabolic effects in 3D culture of primary chondrocytes.

**Discussion**

Inflammatory and catabolic processes triggered by IL-1β play an important role in the destruction of cartilage in chronic joint diseases such as OA or RA. In the present study, we investigated miRNA-mediated post-transcriptional control of a key mediator of OA, HIF-2α, which is regulated by IL-1β in human chondrocytes. Using an unbiased bioinformatics analysis of IL-1β-stimulated miRNAs, we identified a putative binding site for miR-365.
site for miR-365 in the 3′ UTR of the catabolic transcription factor HIF-2α. MiR-365 expression was markedly suppressed in OA compared to normal cartilage, and was shown to actively suppress the expression of various HIF-2α-regulated catabolic factors in chondrocytes.

Mammalian cells sense oxygen depletion and modulate the expression of various genes to maintain oxygen homeostasis. Chondrocytes located in the articular cartilage, an avascular tissue, are particularly susceptible to low oxygen pressure, with hypoxia regarded as an important factor for chondrocyte differentiation and cartilage matrix synthesis. Previous reports have shown that chondrocyte gene expression profiles are significantly influenced by the HIF pathway, which may be activated by two structurally similar isoforms, HIF-1α and HIF-2α, which dimerize with HIF-1β. HIF-1α induces cartilage formation and inhibits chondrocyte hypertrophy and endochondral ossification through the BMP2 signaling pathway. Targets of this pathway include a diverse set of genes, including VEGF-A, IGFBP-3, iNOS, and leptin, all of which are enhanced during OA progression. Outside of hypoxia, mechanical stress and inflammatory cytokines have been shown to activate HIF-1 in OA cartilage. Induction of HIF-2α by IL-1β was reported in articular chondrocytes as well as cardiac myocytes. Compared to cartilage, HIF-2α-regulated by IL-1β in cardiac myocytes play a role in the adaptation of the cardiac myocytes during heart failure ameliorating cardiac function. Thus, the role IL-1 regulated HIF-2α may vary according to cells and tissue. In contrast, HIF-2α-mediated signaling in cartilage leads to tissue destruction and progression of OA. HIF-2α activation has been shown to stimulate chondrocyte hypertrophy and endochondral ossification, while suppressing autophagy. In a Japanese population-based cohort study, a single nucleotide polymorphism in the promoter region of human HIF-2α was strongly associated with knee OA. Furthermore, HIF-2α-heterozygous deleted mice are protected from experimental OA induced by destabilization of the medial meniscus or collagenase injection, suggesting HIF-2α is a catabolic regulator responsible for OA cartilage destruction. Furthermore, intra-articular injection of an HIF-2α overexpression vector was sufficient to induce OA development in a mouse model of knee OA. Finally, nicotinamide phosphoribosyltransferase, a
catabolic regulator of OA, was found to be modulated by HIF-2α. The data presented here indicated an increase in HIF-2α expression in OA cartilage, suggesting that HIF-2α is a crucial mediator of cartilage destruction and OA development.

Figure 5. Effect of miR-365 on IL-1β-activated signaling pathways in human chondrocytes. Human OA chondrocytes were transfected with miR-365 or a nonspecific control miRNA (miR-con) for 48 h and stimulated with IL-1β (1 ng/mL) for 0, 15, 30, and 60 min. (A) Phosphorylation of Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 and (C) translocation of p65 into the nucleus were analyzed by Western blot. Immunoblots shown are representative of more than three independent experiments. β-actin and TBP served as loading control. TBP, Tata-box binding protein. (B) The relative phosphorylation level of JNK, ERK, and p38 proteins and (D) the relative level of p65 in the nucleus and cytoplasm. Protein density was normalized to (B) the respective unphosphorylated proteins and (D) β-actin or TBP. Data are expressed as the mean ± SD of more than three independent experiments. ns, not significant, *P < 0.05 vs. miR-con-transfected cells.
**Figure 6.** Suppression of IL-1β-mediated catabolic effect by miR-365. Human OA chondrocytes were transfected with miR-365 or miR-con and si-con or si-HIF-2α for 48 h and stimulated with IL-1β (1 ng/mL) for 24 h. (A) Expression of HIF-2α, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in cell lysates and (C) matrix metalloproteinases (MMP-1 and -3) in the culture medium were analyzed by Western blot. Beta-actin (β-actin) was used as a loading control. The immunoblots shown are representative of three or more independent experiments. (B) Protein density was normalized to β-actin. Data are expressed as the mean ± SD of more than three independent experiments. ns, not significant, *P < 0.05 vs. miR-con-transfected cells. (E) MMP-13 levels in the culture medium were measured by enzyme-linked immunosorbent assay (ELISA). Data are expressed as the mean ± SD of duplicate data from more than three independent experiments. ns, not significant, *P < 0.05 vs. miR-con treated cells.
Increasing evidence has showed that alteration of miRNA expression is linked to the pathogenesis of many diseases, including OA\textsuperscript{15,16}. It has been reported that miR-365 plays a role in a variety of cellular processes including cell proliferation, apoptosis, and differentiation. MiR-365 was shown to confer anti-tumor activity in multiple human cancer cell lines by means of cell cycle regulation and induction of apoptosis\textsuperscript{41–43}. It was also reported that miR-365 regulates IL-6 expression via the MAPK/ERK pathway in HEK293 and Hela cells, while enhanced expression of IL-6 in macrophages of patients with pulmonary tuberculosis is associated with downregulation of miR-365\textsuperscript{44,45}. MiR-365 was identified as a mechanoresponsive microRNA in primary chicken chondrocytes cultured in 3-dimensional collagen scaffolds under cyclic loading\textsuperscript{28}. MiR-365 downregulated HDAC4, resulting in decreased chondrocyte hypertrophy indicating that miR-365 is an important regulator of both chondrocyte hypertrophy and differentiation\textsuperscript{28}. Hydrostatic pressure suppressed the expression of miR-365 and downregulation of HDAC4 in OA chondrocytes, possibly leading to decrease in catabolic activities of chondrocytes\textsuperscript{29,46}. In contrast to our result, previous reports showed that miR-365 was up-regulated by IL-1\textbeta\textsuperscript{β} stimulation and in rat anterior cruciate ligament (ACL) surgery induced OA cartilage as well as human OA cartilage\textsuperscript{29,46}. However, our result showed that both at 1 and 10 ng/mL IL-1\textbeta\textsuperscript{β} decreased miR-365 expression which persisted throughout the experiment duration spanning from 1 to 48 hours. The average age of cartilage donors (approximately 71 yrs vs 62.7 or 56.2 yrs), and control specimens classification (cartilage from the femoral head of patients with femur neck fracture and no known history of OA or RA vs cartilage (normal looking non-loaded area) from patient with primary or traumatic OA) might have caused the discrepancy in miR-365 expression in OA cartilage. Our luciferase assay confirmed that miR-365 directly interacts with the 3′UTR of HIF-2\alpha mRNA. Downregulation of miR-365 resulted in the increased expression of HIF-2\alpha and MMP-13 as well as a variety of other catabolic genes, including COX2, iNOS, and MMP-1, and -3, all of which are under the control of HIF-2\alpha\textsuperscript{9}. These results suggest that miR-365 alleviates IL-1\textbeta\textsuperscript{β}-induced catabolism by modulating HIF-2\alpha at the posttranscriptional level, and through cross-regulation of MAPK-NF-kB signaling. A recent study reported that the clinically approved HDAC inhibitor Vorinostat specifically increases HIF-2\alpha in soft tissue sarcoma cell\textsuperscript{47}. Whether the regulation of HIF-2\alpha by HDAC4 in chondrocytes is an upstream event of the catabolic regulation by miR-365 is a subject of further research. Considering the role of HIF-2\alpha in the regulation of cartilage degradation, these data strongly implicate miR-365 as a potential therapeutic target for the treatment of OA, though significant obstacles still remain in terms of miRNA delivery and possible off-target effects due to redundant biological targets of a single miRNA.
In summary, we demonstrate that miR-365 levels were significantly suppressed in OA cartilage, and that IL-1β decreased the level of miR-365 in articular chondrocytes through activation of MAPK and NF-κB signaling pathways. miR-365 suppressed IL-1β-mediated catabolic responses in monolayer and 3D culture of articular chondrocytes, with concurrent regulation of HIF-2α expression, suggesting that miR-365 could be a useful target for OA therapy.

References

1. Goldring, M. B. The role of the chondrocyte in osteoarthritis. *Arthritis Rheum* 43, 1916–1926 (2000).
2. Dareshia, M. & Yao, J. Q. The interleukin Ibeta pathway in the pathogenesis of osteoarthritis. *J Rheumatol* 35, 2306–2312 (2008).
3. Sasaki, K. et al. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. *J Biochem* 123, 431–439 (1998).
4. Towle, C. A. et al. Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/paracrine role in pathogenesis. *Osteoarthr Cartilage* 5, 293–300 (1997).
5. Wood, D. D., Ihrle, E. J., Dinarello, C. A. & Cohen, P. L. Isolation of an interleukin-1-like factor from human joint effusions. *Arthritis Rheum* 26, 975–983 (1983).
6. Martin, G. et al. Effect of hypoxia and reoxygenation on gene expression and response to interleukin-1 in cultured articular chondrocytes. *Arthritis Rheum* 50, 3549–3560 (2004).
7. Sartori-Cinzia, A. R., Mara, C. S., Argolo, D. L. & Coimbra, I. B. Regulation of hypoxia-inducible factor-1alpha (HIF-1alpha) expression by interleukin-1beta (IL-1 beta), insulin-like growth factors I (IGF-I) and II (IGF-II) in human osteoarthritic chondrocytes. *Clinics (Sao Paulo)* 67, 35–40 (2012).
8. Wann, A. K., Thompson, C. L., Chapple, J. P. & Knight, M. M. Detection of interleukin-1beta sequesters hypoxia inducible factor 2alpha to the primary cilium. *Cilia* 2, 17 (2013).
9. Yang, S. et al. Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. *Nat Med* 16, 687–693 (2010).
10. Patel, S. A. & Simon, M. C. Biology of hypoxia-inducible factor-2alpha in development and disease. *Cell Death Differ* 15, 628–634 (2008).
11. Ratcliffe, P. J. H. I. F. -1 and HIF-2: working alone or together in hypoxia? *J Clin Invest* 117, 862–865 (2007).
12. Saito, T. et al. Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. *Nat Med* 16, 678–686 (2010).
13. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116, 281–297 (2004).
14. Nugent, M. MicroRNAs: exploring new horizons in osteoarthritis. *Osteoarthr Cartilage* 24, 573–580 (2016).
15. Park, S. J., Cheon, E. J. & Kim, H. A. MicroRNA-558 regulates the expression of cyclooxygenase-2 and IL-1beta-induced catabolic effects in human articular chondrocytes. *Osteoarthr Cartilage* 21, 981–989 (2013).
16. Park, S. J., Cheon, E. J., Lee, M. H. & Kim, H. A. MicroRNA-127-5p regulates matrix metalloproteinase 13 expression and interleukin-1beta-induced catabolic effects in human chondrocytes. *Arthritis Rheum* 65, 3141–3152 (2013).
17. Akhtar, N. et al. MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritic chondrocytes. *Arthritis Rheum* 62, 1361–1371 (2010).
18. Blau, E. A. et al. miR-199a, a bone morphogenetic protein 2-responsive MicroRNA, regulates chondrogenesis via direct targeting to Smad1. *J Biol Chem* 288, 11326–11335 (2013).
19. Miyaki, S. et al. MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses. *Arthritis Rheum* 60, 2723–2730 (2009).
20. Blanco, F. J. & Ruiz-Romo, C. New targets for disease modifying osteoarthritis drugs: chondrogenesis and Runx1. *Ann Rheum Dis* 72, 631–634 (2013).
21. Bouve, S. et al. Regulation of aggrecanases from the ADAMTS family and aggrecan neoepitope formation during in vitro chondrogenesis of human mesenchymal stem cells. *Eur Cell Mater* 23, 320–332 (2012).
22. Culbert, A. L. et al. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification. *Stem Cells* 32, 1289–1300 (2014).
23. LeBlanc, K. T. et al. Runx1 Activities in Superficial Zone Chondrocytes, Osteoarthritic Chondrocyte Clones and Response to Mechanical Loading. *J Cell Physiol* 230, 440–448 (2015).
24. Li, M. et al. miR365 overexpression promotes cell proliferation and invasion by targeting ADAMTS-1 in breast cancer. *Int J Oncol* 47, 296–302 (2015).
25. Mitani, H. et al. Comparison of age-dependent expression of aggrecan and ADAMTSs in mandibular condylar cartilage, tibal growth plate, and articular cartilage in rats. *Histochem Cell Biol* 126, 371–380 (2006).
26. Mura, M. et al. The role of the 3’UTR region in the regulation of the ACVR1/Alk2 gene expression. *PLoS One* 7, e50958 (2012).
27. Sun, L. et al. Mir193b-365 is essential for brown fat differentiation. *Nat Cell Biol* 13, 958–965 (2011).
28. Guan, Y. J., Yang, X., Wei, L. & Chen, Q. MiR-365: a mechanosensitive microRNA stimulates chondrocyte differentiation through targeting histone deacetylase 4. *FASEB J* 25, 4457–4466 (2011).
29. Chelieschi, S. et al. Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/beta-Catenin Pathway. *Int J Mol Sci* 18, 133 (2017).
30. Bellucci, F. et al. Synovial fluid levels of bradykinin correlate with biochemical markers for cartilage degradation and inflammation in knee osteoarthritis. *Osteoarthr Cartilage* 21, 1774–1780 (2013).
31. Mabey, T. et al. Plasma and synovial fluid inflammatory cytokine profiles in primary knee osteoarthritis. *Biomarkers* 21, 639–644 (2016).
32. Lee, H. H. et al. Hypoxia enhances chondrogenesis and prevents terminal differentiation through PI3K/Akt/FoxO dependent anti-apoptotic effect. *Sci Rep* 3, 2683 (2013).
33. Zhou, N. et al. HIF-1alpha as a Regulator of BMP2-Induced Chondrogenic Differentiation, Osteogenic Differentiation, and Endochondral Ossification in Stem Cells. *Cell Physiol Biochem* 36, 44–80 (2015).
34. Pfander, D., Cramer, T. & Swoboda, B. Hypoxia and HIF-1alpha in osteoarthritis. *Int Orthop* 29, 6–9 (2005).
35. Hashimoto, S. et al. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. *Arthritis Rheum* 41, 1266–1274 (1998).
36. Grosfeld, A. et al. Hypoxia increases leptin expression in human PAZ6 adipose cells. *Diabetologia* 45, 527–530 (2002).
37. Grosfeld, A. et al. Hypoxia-inducible factor 1a regulates the expression of Ccl4 in retinal cells. *Cell Physiol Biochem* 277, 4295–4297 (2002).
38. Banakul, T. et al. Endothelial PAS domain protein 1 (EPAS1) induces adrenomedullin gene expression in cardiac myocytes: role of EPAS1 in an inflammatory response in cardiac myocytes. *J Mol Cell Cardiol* 54, 739–748 (2002).
39. Bohensky, J. et al. Regulation of autophagy in human and murine cartilage: hypoxia-inducible factor 2 suppresses chondrocyte autophagy. *Arthritis Rheum* 60, 1406–1415 (2009).
40. Yang, S. et al. NAMPT (visfatin), a direct target of hypoxia-inducible factor-2alpha, is an essential catabolic regulator of osteoarthritis. *Ann Rheum Dis* 74, 595–602 (2015).
41. Zhou, M. et al. A novel onco-mir-365 induces cutaneous squamous cell carcinoma. *Carcinogenesis* 34, 1653–1659 (2013).
42. Singh, R. & Saini, N. Downregulation of BCL2 by miRNAs augments drug-induced apoptosis—a combined computational and experimental approach. *J Cell Sci* **125**, 1568–1578 (2012).

43. Nie, J. et al. microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. *Carcinogenesis* **33**, 220–225 (2012).

44. Xu, Z. et al. miR-365, a novel negative regulator of interleukin-6 gene expression, is cooperatively regulated by Sp1 and NF-kappaB. *J Biol Chem* **286**, 21401–21412 (2011).

45. Song, Q. et al. MicroRNA-365 in macrophages regulates Mycobacterium tuberculosis-induced active pulmonary tuberculosis via interleukin-6. *Int J Clin Exp Med* **8**, 21401–21412 (2015).

46. Yang, X. et al. Mechanical and IL-1beta Responsive miR-365 Contributes to Osteoarthritis Development by Targeting Histone Deacetylase 4. *Int J Mol Sci* **17**, 436 (2016).

47. Nakazawa, M. S. et al. Epigenetic re-expression of HIF-2alpha suppresses soft tissue sarcoma growth. *Nat Commun* **7**, 10539 (2016).

**Acknowledgements**

This study was supported by a grant (HI14C2248 and HI15C2699) from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea, the Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education (2014R1A1A2059823), and in part by Hallym University Research Fund. We would like to thank In Young Park for her assistance with histological processing.

**Author Contributions**

H.S.H. and H.A.K. conceived and designed the study, conducted data interpretation, and wrote manuscript. S.J.P. and M.H.L. were involved in the conception and design of the study and acquisition and analysis of data. All authors also drafted and revised the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors have read and approved the final manuscript for publication.

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017